Corcept Therapeutics Incorporated (NASDAQ: CORT) is one of the best mid cap growth stocks to invest in now. Earlier on June 5 ...

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients ...

Investigators examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes.

Multimorbidity is common in SSc and is linked to reduced survival and physical function, particularly among patients with cardiovascular and renal comorbidities.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Retrospective, real-world data analysis showed pts with MM who received BsAbs and developed VTE had significantly shorter OS and higher risk of death.

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...